Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180853 · ClinicalTrials.gov registry record
Multiple Myeloma Patient Registry
A clinical trial, sponsored by Janssen Scientific Affairs.
- Terminated
- Registry status
- 85
- Enrollment target
NCT03180853 is a clinical trial that was terminated before completion, run by Janssen Scientific Affairs. The registered enrollment target is 85 participants.
The verdict
NCT03180853 was terminated before completion, sponsored by Janssen Scientific Affairs.
- TERMINATED
- Registry status
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2018-04-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180853
The ClinicalTrials.gov registry entry for NCT03180853 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03180853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03180853 about?
NCT03180853 is a clinical study titled "Multiple Myeloma Patient Registry". The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/o...
What is the current status of trial NCT03180853?
This trial is currently terminated. The enrollment target is 85 participants. The study started on 2017-05-08. Estimated completion is 2018-04-06.
Who is sponsoring clinical trial NCT03180853?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.